BDRON 250 MG

The defining feature of Abiraterone acetate is its cyp17 inhibitor activity. Inhibits CYP17A1, suppressing androgen biosynthesis in the testes, adrenals and tumor tissue. Hormone-pathway suppression is the central therapeutic principle, with treatment selection shaped by the prostate cancer disease state or other hormone-sensitive context described in the indication. Within this database it is listed under Hormonal / Endocrine Therapy; Androgen-Synthesis Inhibitor. The principal indications are Metastatic castration-resistant prostate cancer; metastatic hormone-sensitive/castration-sensitive prostate cancer in combination with ADT and corticosteroid, with Prostate Cancer identified as the associated tumor types. Its treatment role can differ substantially between these settings, so the disease context matters as much as the drug class. Regimens listed for the medicine include Abiraterone + prednisone/prednisolone; abiraterone + androgen-deprivation therapy (ADT); combination AR-pathway regimens. The database places it within endocrine management, where the hormonal environment and disease state are important determinants of clinical use. Where a molecular alteration, receptor status, or prior-treatment requirement appears in the indication, that criterion is part of the clinical context rather than an optional detail. The medicine may consequently occupy an induction, maintenance, adjuvant, metastatic, salvage, or supportive position depending on the setting recorded here. The summary is descriptive and does not provide individualized dosing or administration instructions. Current product information and disease-specific guidance should be checked before clinical application.